Company news
Medexus Pharmaceuticals Inc. (TSX:MDP) news
Every Medexus Pharmaceuticals Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date
August 10, 2026
Medexus Schedules First Fiscal Quarter 2027 Conference Call
July 30, 2026
Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection
June 25, 2026
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
June 16, 2026
Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
June 9, 2026
Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation
April 15, 2026
Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
February 11, 2026
Medexus Schedules Third Fiscal Quarter 2026 Conference Call
February 3, 2026
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
November 20, 2025
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
November 17, 2025
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
November 12, 2025
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
November 4, 2025
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
September 25, 2025
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection
August 12, 2025
Medexus Schedules First Fiscal Quarter 2026 Conference Call
August 5, 2025
GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026
August 5, 2025
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
June 25, 2025
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call
June 17, 2025
Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada
April 17, 2025
Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection
April 7, 2025
Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.
March 14, 2025
Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection
February 24, 2025
Canadian Investment Regulatory Organization Trade Resumption - MDP
February 6, 2025
Canadian Investment Regulatory Organization Trading Halt - MDP
February 6, 2025
Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States
February 5, 2025
Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada
February 4, 2025
Medexus Schedules Third Fiscal Quarter 2025 Conference Call
January 31, 2025
Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares
January 31, 2025
Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update
January 22, 2025
Medexus and British Columbia's Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, Canada
January 15, 2025
Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement, Setting Regulatory Milestone Amounts and Payment Schedule
December 2, 2024
Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada
November 18, 2024
Medexus Announces Strong Fiscal Q2 2025 Results
November 7, 2024
Medexus Schedules Second Fiscal Quarter 2025 Conference Call
October 29, 2024
Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date
September 16, 2024
Medexus Announces Strong Fiscal Q1 2025 Results
August 7, 2024
Medexus Schedules First Fiscal Quarter 2025 Conference Call
July 30, 2024
Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024
June 25, 2024
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call
June 18, 2024
FDA Accepts for Review Treosulfan NDA Resubmission
June 6, 2024
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada
May 1, 2024
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 2, 2024
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
March 26, 2024
Medexus Announces Fiscal Q3 2024 Results
February 7, 2024
Medexus Schedules Third Fiscal Quarter 2024 Conference Call
January 30, 2024
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine
January 8, 2024
Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million
November 8, 2023
Medexus Schedules Second Fiscal Quarter 2024 Conference Call
November 1, 2023
Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering
October 17, 2023
Medexus Fully Repays Convertible Debentures In Cash At Maturity
October 16, 2023